EU/3/06/404

Table of contents

About

On 23 October 2006, orphan designation (EU/3/06/404) was granted by the European Commission to Gendux AB, Sweden, for adenoviral vector containing human p53 gene for the treatment of Li-Fraumeni syndrome.

The sponsorship was transferred to Gendux Molecular Limited, Ireland, in December 2007.

Key facts

Active substance
Adenoviral vector containing human p53 gene
Disease / condition
Treatment of Li Fraumeni Syndrome
Date of first decision
23/10/2006
Outcome
Positive
EU designation number
EU/3/06/404

Sponsor's contact details

Gendux Molecular Limited
70 Sir John Rogerson’s Quay
Dublin 2
Ireland
Telephone: +353 1 849 1400
Telefax: +353 1 849 1401
E-mail: info@gendux.ie

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Teenage Cancer Trust
    3rd floor
    93 Newman Street
    London W1T 3EZ
    United Kingdom
    Telephone: +44 20 7612 0370
    Telefax: +44 20 7612 0371
    E-mail: tct@teenagecancertrust.org
  • Ligue Nationale contre le Cancer (LNCC)
    12, rue Corvisart
    75013 Paris
    France
    Telephone : +33 1 53 55 24 00
    Telefax : +33 1 43 36 91 10
    E-mail: ligue@ligue-cancer.net
  • Deutsche Krebshilfe e.V.
    Buschstrasse 32
    53113 Bonn
    Postfach 1467
    53004 Bonn
    Germany
    Telephone: +49 2 28 72 99 00
    Telefax: +49 22 87 29 90 11
    E-mail: deutsche@krebshilfe.de

How useful was this page?

Add your rating